Results 151 to 160 of about 5,988 (201)
The importance of dosing frequency on the safety of DOACs
American Heart Journal Plus, 2022 Direct oral anticoagulants (DOACs) represent a significant advance over vitamin K antagonists, such as warfarin in patients with atrial fibrillation (AF), due to their favorable risk-benefit profile, with significant reductions in stroke and serious bleeding, particularly intracranial hemorrhage.1 Although as class, DOACs tend to reduce major bleeding ...
Christian T Ruff
exaly +4 more sources
American Journal of Emergency Medicine, 2021 Background: Although the preliminary evidence seems to confirm a lower incidence of post-traumatic bleeding in patients treated with direct oral anticoagulants (DOACs) compared to those on vitamin K antagonists (VKAs), the recommended management of mild ...
Arian Zaboli +2 more
exaly +2 more sources
Exploring the Perioperative Use of DOACs, off the Beaten Track
Journal of Clinical MedicineA notable increase in direct oral anticoagulant (DOAC) use has been observed in the last decade. This trend has surpassed the prescription of vitamin K antagonists (VKAs) due to the absence of the need for regular laboratory monitoring and the more ...
Iris Parrini +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drug and Therapeutics Bulletin, 2020
Abstract Review of: Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents.
openaire +2 more sources
Abstract Review of: Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents.
openaire +2 more sources
Gender-Associated Variation in DOAC Levels
Clinical Laboratory, 2023Direct oral anticoagulants (DOAC) such as Xa inhibitors rivaroxaban (riva) and apixaban (apix) are increasingly replacing Vitamin K antagonists in prophylaxis and treatment of venous thromboembolism (VTE). Measurements of DOAC plasma levels may be necessary in certain clinical conditions to determine the further dosage.
Anja, Moldenhauer +3 more
openaire +2 more sources
DOAC dosing in renal impairment
Drug and Therapeutics Bulletin, 2019Dabigatran was the first direct acting oral anticoagulant (DOAC) launched in the UK and has been in clinical use for over 10 years. Since then, ▾rivaroxaban, apixaban and ▾edoxaban have been marketed, and between them the four DOACs account for over 800 000 prescriptions per month in England.1 DOACs provide some advantages over warfarin, including a ...
openaire +2 more sources
CNS Drugs, 2023
The use of direct oral anticoagulants (DOACs) is increasing because of their superior efficacy and safety compared with vitamin K antagonists. Pharmacokinetic drug interactions, particularly those involving cytochrome P450- mediated metabolism and P-glycoprotein transport, significantly affect the efficacy and safety of DOACs.
Rachel Goldstein +5 more
openaire +2 more sources
The use of direct oral anticoagulants (DOACs) is increasing because of their superior efficacy and safety compared with vitamin K antagonists. Pharmacokinetic drug interactions, particularly those involving cytochrome P450- mediated metabolism and P-glycoprotein transport, significantly affect the efficacy and safety of DOACs.
Rachel Goldstein +5 more
openaire +2 more sources
Thrombosis Research, 2019
The recent approval of direct-acting oral anticoagulants (DOAC) for long-term anticoagulation in atrial fibrillation and venous thromboembolism resulted in a rapid implementation of these new drugs into daily care. Although DOAC dosing is similar for women and men and, overall, results in comparable outcomes, sex specific issues need to be considered ...
openaire +3 more sources
The recent approval of direct-acting oral anticoagulants (DOAC) for long-term anticoagulation in atrial fibrillation and venous thromboembolism resulted in a rapid implementation of these new drugs into daily care. Although DOAC dosing is similar for women and men and, overall, results in comparable outcomes, sex specific issues need to be considered ...
openaire +3 more sources
Pharmacokinetics and Pharmacodynamics of DOAC
2021Direct oral anticoagulants (DOACs) have become available as an alternative to warfarin anticoagulation in non-valvular atrial fibrillation. The DOACs, dabigatran (a reversible direct thrombin inhibitor) and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban offer fixed dosing, more predictable pharmacokinetics and fewer interactions ...
openaire +1 more source
DOAC prescribing in people with renal impairment
Drug and Therapeutics Bulletin, 2023Abstract Overview of: Joy M, Williams J, Emanuel S, et al. Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014–2019). Heart 2022. doi: 10.1136/heartjnl-2022-321377. [Epub ahead of print 9 Sept 2022].
openaire +2 more sources